Legal
As Novartis looks to regain its reputation following a series of ethical blunders, the company unveiled a new ethics scoring system that will be tied to employee bonuses.
The U.S. House of Representatives has split with the Senate over requiring pharmaceutical companies to disclose the list price of their prescription medications in television advertisements.
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA’s decision to delay a ruling for its Parkinson’s disease treatment.
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
Purdue Pharma, best known for being the manufacturer of opioid drug OxyContin, is offering free doses of a treatment for opioid abuse as part of negotiations in more than 1,000 lawsuits.
Adaptimmune Therapeutics plc today announced that it has entered into a definitive agreement with Matrix Capital Management Company
Oncolytics Biotech® Inc. today announced that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the company’s clinical development program.
Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note today as well. Let’s take a look.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center came under fire this weekend for his failure to disclose financial ties to various pharmaceutical companies when he published research papers in peer-reviewed journals.
PRESS RELEASES